ZIVO Bioscience, Inc. Share Price

Equities

ZIVO

US98978N3098

Food Processing

Market Closed - OTC Markets 17:20:35 26/04/2024 BST 5-day change 1st Jan Change
8.1 USD +1.25% Intraday chart for ZIVO Bioscience, Inc. +1.25% +575.00%
Sales 2024 * 545K 43.63M Sales 2025 * 1.51M 121M Capitalization 22.7M 1.82B
Net income 2024 * -8M -640M Net income 2025 * -8M -640M EV / Sales 2024 * 41.7 x
Net cash position 2024 * - 0 Net cash position 2025 * - 0 EV / Sales 2025 * 15.1 x
P/E ratio 2024 *
-2.93 x
P/E ratio 2025 *
-3.68 x
Employees 8
Yield 2024 *
-
Yield 2025 *
-
Free-Float 59.42%
More Fundamentals * Assessed data
Dynamic Chart
ZIVO Bioscience, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
ZIVO Bioscience, Inc. Reports Additional Findings from Positive 42-Day Coccidiosis Challenge Study CI
Zivo Bioscience Reports Positive Efficacy Results from 42-Day Validation Study with Non-Antibiotic Immune-Modulating Product for the Prevention and Treatment of Coccidiosis in Broiler Chickens CI
ZIVO Bioscience, Inc. announced that it has received $0.531142 million in funding CI
ZIVO Bioscience, Inc. announced that it expects to receive $0.531142 million in funding CI
ZIVO Bioscience, Inc. announced that it has received $0.308936 million in funding CI
ZIVO Bioscience, Inc. announced that it expects to receive $0.308936 million in funding CI
ZIVO Bioscience, Inc. announced that it has received $0.2 million in funding CI
ZIVO Bioscience, Inc.(NasdaqCM:ZIVO) dropped from S&P TMI Index CI
ZIVO Bioscience, Inc.(OTCPK:ZIVO) dropped from NASDAQ Composite Index CI
ZIVO Bioscience, Inc. announced that it expects to receive $0.15 million in funding CI
ZIVO Bioscience, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Zivo Bioscience Insider Bought Shares Worth $199,600, According to a Recent SEC Filing MT
Zivo Says Trial Results Confirm Efficacy of Non-Antibiotic Product Candidate for Treating Coccidiosis in Broiler Chickens MT
Trial Results Confirm Efficacy of ZIVO Bioscience?s Non-Antibiotic Product Candidate for the Prevention and Treatment of Coccidiosis in Broiler Chickens CI
More news
1 day+1.25%
1 week+1.25%
Current month+4.52%
1 month+1.25%
3 months-19.00%
6 months+141.11%
Current year+575.00%
More quotes
1 week
7.00
Extreme 7
8.10
1 month
6.81
Extreme 6.81
8.10
Current year
1.35
Extreme 1.35
13.00
1 year
0.48
Extreme 0.48
19.08
3 years
0.48
Extreme 0.48
72.00
5 years
0.48
Extreme 0.48
86.40
10 years
0.48
Extreme 0.48
110.35
More quotes
Managers TitleAgeSince
Chief Executive Officer 76 18/07/13
Director of Finance/CFO 61 31/12/20
Chief Tech/Sci/R&D Officer - 30/06/21
Members of the board TitleAgeSince
Director/Board Member 77 16/09/14
Director/Board Member 58 27/08/13
Chief Executive Officer 76 18/07/13
More insiders
Date Price Change Volume
26/04/24 8.1 +1.25% 1,175
19/04/24 8 0.00% 647
18/04/24 8 +15.94% 270

Delayed Quote OTC Markets, April 26, 2024 at 05:20 pm

More quotes
Zivo Bioscience, Inc. is a research and development company. The Company operates in both the biotech and agtech sectors, with an intellectual property portfolio comprised of algal and bacterial strains, biologically active molecules and complexes, production techniques, cultivation techniques and patented or patent-pending inventions for applications in human and animal health. Its product candidates are at different stages of development for different applications. It is developing a product candidate targeting poultry gut health. It is developing products for Bovine Mastitis, Canine Joint Health, Human Immune Modulation, Algal biomass for human consumption, and Biomass for supporting skin health/anti-aging. It is focused on licensing and selling natural bioactive ingredients derived from their proprietary algae cultures to animal, human and dietary supplement, and medical food manufacturers.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
8.1 USD
Average target price
12 USD
Spread / Average Target
+48.15%
Consensus